A pilot study to investigate cardiac adverse effects of ropivacaine using local infiltration anaesthesia (LIA) technique during total hip arthroplasty (THA).
Completed
- Conditions
- Total Hip Artroplasty (THA) / total hip replacement10007521
- Registration Number
- NL-OMON38715
- Lead Sponsor
- Reinier de Graaf Groep
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Patients 18 years and older and scheduled for THA in Reinier de Graaf hospital.
Exclusion Criteria
Allergy for ropivacaine.
Moderate or severe cardiac disease, bronchial asthma (severe valave insuffiency, angina pectoris 2/4 or more, congestive heart failure, rhythmic disorder).
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is QRS widening (delta QRS) and delta QTc-intervals<br /><br>measured with a 24 hour Holter ECG compared to baseline ECG.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary study outcomes are bradycardia and/or tachycardia, and/or<br /><br>ST-elevation compared to basaeline ECG.</p><br>